Markus Ploesser, MD
Forensic Psychiatry · Chula Vista, CANPI 1669662755
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $115,250 of the $156,914 with a category attached, or 73.4%. 22 manufacturers reported payments, led by Alkermes, Inc. at 38.1% of the total. Among forensic psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 589 payments — averaging $266.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$60K
- Teva Pharmaceuticals USA, Inc.$52K
- Indivior Inc.$34K
- Otsuka America Pharmaceutical, Inc.$3K
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- plus $4K from 16 others
What the payments were for
- Consulting fees$7,4605%
- Speaking & faculty fees$115,25073%
- Travel & lodging$11,9968%
- Food & beverage$21,93014%
- Education$2770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 162 | $59,820 |
| Teva Pharmaceuticals USA, Inc. | 90 | $52,360 |
| Indivior Inc. | 107 | $33,903 |
| Otsuka America Pharmaceutical, Inc. | 59 | $2,537 |
| Neurocrine Biosciences, Inc. | 42 | $1,943 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 47 | $1,929 |
| Johnson & Johnson | 19 | $996 |
| Axsome Therapeutics, Inc. | 8 | $841 |
| AbbVie | 13 | $468 |
| Vanda Pharmaceuticals Inc. | 12 | $400 |
| Medtronic | 5 | $349 |
| E.r. Squibb & Sons, L.L.C. | 7 | $284 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $180 |
| Avanos Medical | 1 | $163 |
| Boston Scientific | 1 | $162 |
| Brainsway USA Inc | 1 | $149 |
| Abbott | 1 | $147 |
| Acadia Pharmaceuticals Inc | 2 | $119 |
| Sunovion Pharmaceuticals Inc. | 4 | $85 |
| Neuronetics, Inc. | 2 | $36 |
| SPR Therapeutics, Inc | 1 | $24 |
| Braeburn Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$204,941
- UZEDY$40,528
- PERSERIS$31,986
- AUSTEDO$8,207
- ARISTADA$4,704
- VIVITROL$4,178
- INGREZZA$1,406
- ARISTADA INITIO$1,176
- REXULTI$1,063
- CAPLYTA$927
- Auvelity$724
- ABILIFY MAINTENA$689
- SPRAVATO$361
- INVEGA SUSTENNA$269
- SYNCHROMEDII$175
- COOLIEF* COOLED RADIOFREQUENCY$163
- GENERAL PAIN MANAGEMENT$162
- Brainsway Deep TMS$149
- ETERNA$147
- VRAYLAR$125
How this compares
$156,914 in reported general payments places this provider in the 95th percentile of 43 forensic psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LybalviOlanzapine/Samidorphan Malate | 50 | $76,224 |
| UzedyRisperidone | 16 | $55,853 |
| VivitrolNaltrexone Microspheres | 11 | $18,419 |
| Aripiprazole | 34 | $2,744 |
| Bupropion XlBupropion Hcl | 70 | $1,205 |
| Divalproex Sodium ErDivalproex Sodium | 51 | $1,192 |
| Olanzapine | 55 | $899 |
| Naltrexone Hcl | 11 | $681 |
| Buspirone Hcl | 56 | $451 |
| AmantadineAmantadine Hcl | 12 | $448 |
| Quetiapine Fumarate | 36 | $344 |
| Mirtazapine | 42 | $267 |
| Haloperidol | 15 | $236 |
| Duloxetine Hcl | 29 | $129 |
| Benztropine Mesylate | 18 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Lybalvi, Vivitrol | $59,820 | $94,64361 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $52,360 | $55,85316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 forensic psychiatry providers in California.
Other forensic psychiatry in Chula Vista
- Katrina PetersSan Francisco$15K
- Cameron QuanbeckSacramento$6K
- Anthony CozzolinoSan Jose$3K
- Robin LinSacramento$1K
- Seth CohenAtascadero$1K
- Paul BohnLos Angeles$725
- Edgar CatingubSacramento$596
- Alejandro PerezAtascadero$464
- Praveen KambamLos Angeles$408
- Michael TakamuraPoway$380
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.